Psychedelic Policy Briefing: Ibogaine, Compass, DEA
TITLE: Psychedelic Policy Briefing: FDA Seeks Ibogaine Trial Input, Compass Prepares COMP360 Launch, and DEA Faces State-Level Questions EXCERPT: The latest psychedelic policy developments include the FDA’s request for public…